Navigation Links
PharmaNet Names Dr. George Scott Vice President of Bioanalytical Services
Date:7/18/2011

PRINCETON, N.J., July 18, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc., an inVentiv Health Company and a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that it has appointed George Scott, PhD, as Vice President, Bioanalytical Services. In this role, Dr. Scott will provide leadership for PharmaNet's GLP-compliant bioanalytical laboratories in the United States and Canada. In addition, he will build upon PharmaNet's bioanalytical method development, validation and sample analysis services across the continuum of drug development and lead PharmaNet's geographical and service expansion strategies in bioanalysis.

"Dr. Scott has a very impressive scientific and operational experience base in bioanalysis," commented Riaz Bandali, President, Early Stage Development. "He has extensive knowledge of our clients' needs and is highly regarded in the industry for his scientific expertise and his business acumen."

Prior to joining PharmaNet, Dr. Scott served as Director of Pharmacokinetics and Drug Metabolism at Amgen, a world leader in biotechnology. He was responsible for overseeing the immunochemistry and small molecule bioanalytical capabilities. He was also integrally involved in the Amgen Leadership Committee that managed strategic outsourcing decisions for small molecule and large molecule programs to global bioanalytical service providers. Prior to Amgen, Dr. Scott was responsible for establishing and growing the global ligand binding services at another CRO.

Dr. Scott holds a Bachelors of Science in Neuroscience from Edinburgh University and was awarded a PhD from the University of Nottingham for studies in neuropharmacology. After four years in post-doctoral positions at Dalhousie University and the University of Montreal, he served for two years as an Assistant Professor in the faculty of Dentistry at McGill University.

About PharmaNet

PharmaNet Development Group, Inc., an inVentiv Health Company and a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com.

Contact:  Anne-Marie Hess
Phone:  (609) 951-6842
E-mail:  ahess@pharmanet.com


'/>"/>
SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNets Bioanalytical Laboratory Recognized by the Standards Council of Canada for Good Laboratory Practice Compliance
2. PharmaNet Collaborates With the Cancer Immunotherapy Trials Network
3. PharmaNet and Maisonneuve-Rosemont Hospital Collaborate to Evaluate Innovative Drugs
4. PharmaNet Experts to Showcase Bioanalytical Posters at ASMS 2011
5. JLL Partners Sells PharmaNet
6. inVentiv Health to Acquire PharmaNet
7. Valerie Palumbo Joins PharmaNet as Senior Vice President, Corporate Quality Assurance
8. PharmaNet Shares Expertise in Drug Development Outsourcing at the 2011 Partnerships in Clinical Trials Conference
9. Dr. Jeffrey Freitag Appointed Chief Medical Officer of PharmaNet
10. PharmaNet and Anapharm Europe Formally End Joint Venture
11. Catherine Derasp Joins PharmaNet as Vice President, Clinical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Dr. Vivek Ahuja , ... phen Schmidt Join the Growing ... solutions for life sciences, today announced key new leaders have joined ... to a growing business.  This will bolster the company,s safety business ... joined ArisGlobal in the position of Vice President - Safety. George ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... -- Elekta today announced that its leading-edge ... focal point of seven scientific presentations at ESTRO 35, ... & Oncology, taking place April 29 - May 3. ... and a high-field MRI scanner with sophisticated software that ... in real time. The MR-linac is designed to improve ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Footwear Foundation, the national charitable foundation serving the footwear industry, has broken all ... representing more than 130 companies across 23 states during the months of April ...
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... , ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd annual “Bite ... a light breeze and temperatures in the 60s. Over 400 runners, walkers and volunteers ... and 1-mile walk were held to increase awareness about Lyme disease and to ...
(Date:4/29/2016)... PA (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the ... Prize, the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee ...
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
Breaking Medicine News(10 mins):